The Nucleocapsid Protein of SARS-CoV-2, Combined with ODN-39M, Is a Potential Component for an Intranasal Bivalent Vaccine with Broader Functionality
Article in Viruses (March 2024)
The most recent citing publications are shown below. View all 6 publications that cite this research output on Dimensions.
Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children
Article in International Journal of Infectious Diseases (November 2022)
Recent review of COVID-19 management: diagnosis, treatment and vaccination
Article in Pharmacological Reports (October 2022)